



Announcement Summary

Entity name

CLINUVEL PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Friday July 05, 2024

Details of +securities that have ceased

ASX +security code	Security description	Number of +securities that have ceased	The +securities have ceased due to	Date of cessation
CUV	ORDINARY FULLY PAID	25,985	Cancellation pursuant to an on-market buy-back	30/06/2024
CUVAK	PERFORMANCE RIGHTS	7,357	Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied	01/07/2024

Refer to next page for full details of the announcement



Part 1 - Announcement Details

1.1 Name of +Entity

CLINUVEL PHARMACEUTICALS LIMITED

We (the entity named above) provide the following information about our issued capital.

1.2 Registered Number Type

ABN

Registration Number

88089644119

1.3 ASX issuer code

CUV

1.4 The announcement is

New announcement

1.5 Date of this announcement

5/7/2024



Part 2 - Details of +equity securities or +debt securities that have ceased

ASX +Security Code and Description

CUV : ORDINARY FULLY PAID

Quoted +equity securities or +debt securities that have ceased**Number of securities that have ceased**

25,985

Reason for cessation

Cancellation pursuant to an on-market buy-back

Date of cessation

30/6/2024

Is the entity paying any consideration for the cessation?

Yes

In what currency is the consideration being paid?

AUD - Australian Dollar

Total consideration paid or payable for the securities

AUD 385,731.360000000000

Any other information the entity wishes to notify to ASX about the cessation?

The cessation is with respect to an on-market share buyback, first announced 14 March 2024 and connected to daily buyback notifications lodged 3, 6, 9, 10, 14 May and 4 June 2024.

ASX +Security Code and Description

CUVAK : PERFORMANCE RIGHTS

Unquoted +equity securities that have ceased**Number of securities that have ceased**

7,357

Reason for cessation

Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied

Date of cessation

1/7/2024

Is the entity paying any consideration for the cessation?

No

Any other information the entity wishes to notify to ASX about the cessation?



Part 3 - Issued capital following changes

Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CUV : ORDINARY FULLY PAID	50,077,780

3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CUVAK : PERFORMANCE RIGHTS	258,975

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.